asymmetric thickening and enhancement of the left S1 nerve root. The patient was treated with 1 cycle of R-CHP (rituximab, cyclophosphamide, doxorubicin, and prednisone, i.e. "R-CHOP" omitting "O" vincristine due to preexisting left foot drop), with a plan to add lenalidomide as soon as its off label use was approved by her insurance company. However, lenalidomide was denied; therefore, the plan was revised to R-EPCH (rituximab, etoposide, prednisone, cyclophosphamide, and doxorubicin, i.e. "R-EPOCH" omitting "O" vincristine). Because of the abnormal MRI and PET/CT results in the spinal cord and S1 nerve root, these sites were presumed to be lymphoma and treated with high dose intravenous methotrexate, administered after R-CHP/R-EPCH, and intrathecal methotrexate/cytarabine, as part of the upfront treatment. were biopsied and proven to be DLBCL leg type. Patient was not a candidate for transplantation due to advanced age, therefore she enrolled in a phase I clinical trial evaluating TGR 1202, a phosphatidylinositol-3-kinase delta inhibitor. In the first cycle she clinically had stable disease.
In the midst of cycle 2, she developed many skin lesions consistent with her lymphoma.
PET/CT results were consistent with progression of disease (POD). Next, the patient received three cycles of R-ICE (rituximab, ifosfamide, carboplatin, etoposide), which resolved all the skin lesions and a severely inflamed right 3 rd toe. However, she developed new skin lesions before the planned post-treatment week 6 PET/CT. Subsequently, the patient enrolled in a phase I clinical trial evaluating the combination of 5-azacitidine and romidepsin, and had POD during Extensive workup for relapse was negative, and she improved after holding ibrutinib for 1 week.
She then resumed ibrutinb at 420 mg daily, but had to discontinue it permanently in July 2016 due to severe diarrhea that did not respond to further dose reduction. 
